Гематология / лейкозы / лимфомы

Relapsed/Refractory Multiple Myeloma: Debate — Treatment Selection Between CAR T-Cell and Bispecific Approaches in Second-Line Disease

Relapsed/Refractory Multiple Myeloma: Safety and Real-World Management of BCMA-Directed Therapies

Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 Long-Term Outcomes and Treatment-Free Remission With Cilta-cel

Relapsed/Refractory Multiple Myeloma: MajesTEC-9 and Teclistamab Monotherapy in Lenalidomide and Anti-CD38 Double-Refractory Disease

Relapsed/Refractory Multiple Myeloma: Real-World Treatment Patterns, Attrition, and the Case for Earlier BCMA-Directed Therapy

Shared Decision-Making in Relapsed/Refractory Multiple Myeloma

Evolving Treatment Goals in Multiple Myeloma

Evolution of Frontline Therapy in Multiple Myeloma

Self-Advocacy and Treatment Decisions in Relapsed/Refractory Multiple Myeloma

Study identifies inherited genetic risk factors in childhood leukemia

A study from Karolinska Institutet shows that genetic testing can identify germline predisposition underlying childhood leukemia. The findings, published in Nature Communications, could help enable more personalized treatment and long-term follow-up.

BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma

Why Early Response Testing Could Reshape Lymphoma Treatment

Why Early Response Testing Could Reshape Lymphoma Treatment Cure Today

Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape

Metabolic activity of gut bacteria can either promote or inhibit function of CAR T cells in cancer therapy

Immunotherapies, especially CAR T-cell therapy, have fundamentally changed cancer treatment in recent years, particularly for certain forms of leukemia and lymphoma. Yet not all tumors respond equally well, and the reasons for this remain incompletely understood. A new multicenter study by the Leibniz Institute for…

Sequencing CAR T Therapy and Bispecifics in Follicular and Mantle Cell Lymphoma